NCT05980559View on ClinicalTrials.gov

Evaluation of BTX Injections in Treatment of Bruxism

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

January 15, 2024

Study Completion Date

April 15, 2024

Conditions

Bruxism

Interventions

DRUG

Xeomin

50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally (15 Units per muscle applied with 2 injections in each masseter muscle) (10 Units per muscle applied with 2 injections in each temporalis muscle)

All Listed Sponsors

lead

Alexandria University

OTHER